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Purpose
The aim of this study was to evaluate whether hepatic arterial infusion concurrent chemora-
diotherapy (CCRT) could improve overall survival (OS) in patients with locally advanced 
hepatocellular carcinoma (LAHCC). 
Materials and Methods
Two databases were reviewed from Yonsei Cancer Center (YCC) and Korean Liver Cancer
Study Group (KLCSG) nationwide multi-center hepatocellular carcinoma (HCC) cohort. The
CCRT group included 106 patients, with stage III-IV, Child-Pugh classification A, Eastern 
Cooperative Oncology Group performance status 0 or 1, who underwent definitive CCRT as
the initial treatment at YCC. We used propensity score matching to adjust for seven clinical
factors, including age, tumor size, TNM stage by the Liver Cancer Study Group of Japan, T
stage, Barcelona Clinic Liver Cancer (BCLC) staging system, etiology of HCC, and portal vein
invasion, which all differed significantly in the two databases. From the KLCSG cohort 
enrolled at 32 institutions, 106 patients for the non-CCRT group were defined. 
Results
After propensity score matching, all patient characteristics were balanced between the two
groups. The CCRT group had better OS (median, 11.4) than the non-CCRT group (6.6
months, p=0.02). In multivariate analyses for all patients, CCRT (hazard ratio [HR], 1.48;
95% confidence interval [CI], 1.11 to 1.97; p=0.007), tumor size (HR, 1.08; 95% CI, 1.04
to 1.12; p < 0.001), and BCLC stage (HR, 0.54; 95% CI, 0.36 to 0.8; p=0.003) were inde-
pendent prognostic factors for OS.
Conclusion
CCRT showed better OS for LAHCC patients. In LAHCC patients with a good performance
and normal liver function, CCRT could be a feasible treatment option. All of these findings
need to be validated in prospective clinical trials.
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Introduction
Hepatocellular carcinoma (HCC) is listed as the sixth most
common cancer type and third most common cause of can-
cer-related deaths [1]. According to the Barcelona Clinic
Liver Cancer (BCLC) staging system, potential curative ther-
apies can be applied to early stages of the disease [2]. How-
ever, the majority of HCC patients, who are not in early stage
at the time of the first diagnosis only receive palliative or con-
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servative treatments. 
In cancer treatment, a multimodality approach by a multi-
disciplinary team has been the key principle, using surgery
and radiotherapy (RT) for local and loco-regional sites and
chemotherapy for systemic diseases [3,4]. This principle has
proved to be effective in most cancers [5,6]. Particularly, in
locally advanced cancers, it can induce down-staging to 
resectable status that can be followed by radical resection.
Unfortunately, a multimodality approach involving RT was
not successful for HCC some decades ago [7]. Whole liver 
irradiation with radiation dose less than the tumoricidal level
could be one of the major reasons for the failure in a multi-
modality approach involving RT. 
A recent development of RT technologies allows the deliv-
ery of high doses safely and effectively to localized tumor
volume and has shown a potential to improve survival with-
out severe radiation-related toxicity [8-10]. In the National
Comprehensive Cancer Network (NCCN) guidelines for
HCC, external beam RT is recommended in patients with 
unresectable disease, who are not transplant candidates and
in patients with inoperable local disease despite the evidence
of being category 2B [11]. In our institution, localized con-
current chemoradiotherapy (CCRT) for HCC consisted of
local RT and hepatic arterial infusion chemotherapy (HAIC)
of 5-fluorouracil (5-FU); CCRT was performed to enhance the
effect of local RT and to reduce the risk of intrahepatic metas-
tasis. In several studies at our institution, CCRT showed 
favorable outcomes [12,13]. Several studies from other insti-
tutions reporting about CCRT with HAIC have previously
demonstrated fine treatment outcomes [8,14]. However, due
to the absence of sufficient evidence from phase III random-
ized control trials, the American Association for the Study of
Liver Diseases and the European Association for the Study
of the Liver guidelines do not recommend RT as a treatment
option [2]. 
In Korea, Korean Liver Cancer Study Group (KLCSG) 
established a randomly enrolled nationwide multi-center
HCC cohort between 2003 and 2005 from 32 hospitals in an
effort to generate an optimal management strategy of HCC
[15]. The cohort provides unbiased information regarding
clinical characteristics, treatment patterns, and overall sur-
vival of HCC patients in Korea. However, most patients who
were enrolled in the KLCSG cohort received other monother-
apies, rather than multimodal therapy, such as CCRT as the
first treatment following the diagnosis of locally advanced
HCC. To generate and verify a hypothesis to help implement
a randomized control trial, we utilized the KLCSG cohort as
the control group for comparisons between CCRT and non-
CCRT groups, using propensity score matching. In this
study, we evaluated whether CCRT could improve survival
for locally advanced HCC compared to other treatments,
using propensity score matching.
Materials and Methods
1. Study design
The study was performed and reported in accordance 
to the recommendations of STROBE statement [16]. We 
reviewed two databases: the Yonsei Cancer Center (YCC)
and KLCSG nationwide multi-center HCC cohort. This study
received approval from the internal review boards of partic-
ipating institutions (IRB No. 4-2013-0897). We identified 829
patients who underwent RT for locally advanced HCC at
YCC between 1992 and 2008. Patients were excluded if any
of the following conditions were met: (1) stage I-II disease,
(2) extrahepatic metastasis (not including regional lymph
node involvement), (3) Child-Pugh classification B or C, (4)
CCRT not the first treatment, (5) initially prescribed with 
insufficient irradiated dose for definitive RT (< 40 Gy), (6)
Eastern Cooperative Oncology Group performance status
(ECOG PS) > 2, (7) a history of RT to the abdominal area, or
(8) RT alone or RT with intravenous chemotherapy. After 
exclusions, a total of 106 patients were diagnosed between
1999 and 2008, and patients who underwent hepatic arterial
infusion CCRT definitively as the initial treatment were 
included in the CCRT group. 
The KLCSG nationwide multi-center cohort included 4,522
patients from 2003 to 2005 at 32 Korean institutions. Among
them, 77 patients were excluded due to false information 
regarding the first treatment. Next, 751 locally advanced
HCC patients who underwent other initial treatments 
(except RT) were identified by excluding patients who 
(1) had stage I-II cancer, (2) were given M1 classification, 
(3) were given Child-Pugh classification B or C, (4) received
RT, (5) had missing information for CP class or treatment
type or date, or (6) had false information regarding the treat-
ment aim or diagnosis date. The KLCSG cohort included 
information regarding age, gender, method of diagnosis,
date of diagnosis, date of death, Child-Pugh classification,
TNM stage by Liver Cancer Study Group of Japan (LCSGJ),
tumor size, growth pattern of tumor, tumor invasion into
major vessels, T stage, N stage, M stage, BCLC staging, the
etiology of HCC, type of initial treatment modality, and date
of initial treatment. Among the 751 patients, we assigned 106
patients receiving other monotherapies into the non-CCRT
group by performing 1 to 1 propensity score matching with
the CCRT group.
Staging was determined according to the TNM staging
system of the LCSGJ [17] and BCLC staging system [2]. HCC
was diagnosed depending on the practice guidelines for 
diagnosis and treatment of HCC in KLCSG [18]. HCC was
defined as pathologic confirmation of HCC or compatible 
radiological findings with serum alpha-fetoprotein (AFP)
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level > 400 IU/mL. If AFP levels were ≤ 400 IU/mL, HCC
was diagnosed by radiological findings using at least two 
imaging modalities. 
1) Concurrent chemoradiotherapy
In the CCRT group, the total radiation dose was a median
of 45 Gy (range, 42.4 to 59.4 Gy) in 25 fractions (range, 16 to
33). We defined and delineated the gross tumor volume, clin-
ical target volume (CTV), and planning target volume (PTV)
to determine the prescription dose as described previously
[10]. PTV was defined as CTV surrounded by an additional
5-10 mm margin for setup error and internal organ motion.
We irradiated PTV with a surrounding margin of 1 cm in a
3-dimensional conformal radiotherapy (3D-CRT) in accor-
dance to the dose prescription guidelines [10]. The radiation
dose for a target volume depended on the functional reserve
of the liver and was chosen in a range acceptable to the dose
prescription guideline at each V50% (the normal liver vol-
ume irradiated with more than one-half of the prescription
dose) category. For image-guided intensity-modulated RT
before April 2007, dose prescription was also determined
similar to 3D-CRT. After April 2007, the prescribed radiation
dose was determined according to dose-volume parameters
of the effective irradiated liver volume [10]. Thus, we limited
the mean liver dose to 23 Gy and the maximal dose to 42.24
Gy for the duodenum, stomach, small bowel, and spinal
cord. Concurrent continuous-infusion hepatic arterial 5-FU,
using a percutaneous hepatic arterial catheter inserted via
hepatic arterial angiography, was delivered at a dose of 500
Table 1. Patient characteristics
Variable
CCRT KLCSG cohort
p-value
Non-CCRT 
p-value
(n=106) (n=751) (n=106)
Median age (range, yr) 52 (11-79) 57 (8-83) < 0.001 52 (8-74) 0.99
Median tumor size (range, cm) 10 (2-17) 6 (1-21) < 0.001 10 (2-21) 0.53
Growth pattern Single 31 (29.2) 269 (35.8) 0.18 31 (29.2) > 0.99
Multiple 75 (70.8) 482 (64.2) 75 (70.8)
Sex Male 90 (84.9) 656 (87.4) 0.48 90 (84.9) > 0.99
Female 16 (15.1) 95 (12.6) 16 (15.1)
Child-Pugh classification A 106 (100) 751 (100) > 0.99 106 (100) > 0.99
TNM stage by LCSGJ III 47 (44.3) 585 (77.9) < 0.001 47 (44.3) > 0.99
IV-A 59 (55.7) 166 (22.1) 59 (55.7)
T stage T1 0 ( 2 (0.3) < 0.001 0 ( 0.89
T2 0 ( 12 (1.6) 0 (
T3 48 (45.3) 606 (80.7) 49 (46.2)
T4 58 (54.7) 131 (17.4) 57 (53.8)
N stage N0 97 (91.5) 706 (94.0) 0.32 98 (92.5) 0.8
N1 9 (8.5) 45 (6.0) 8 (7.5)
Portal vein invasion Yes 85 (80.2) 343 (45.7) < 0.001 85 (80.2) > 0.99
No 21 (19.8) 408 (54.3) 21 (19.8)
Hepatic vein invasion Yes 6 (5.7) 77 (10.3) 0.13 13 (12.3) 0.09
No 100 (94.3) 671 (89.7) 93 (87.7)
BCLC staging system A 0 ( 93 (12.4) < 0.001 0 ( 0.85
B 18 (17.0) 247 (32.9) 17 (16.0)
C 88 (83.0) 411 (54.7) 89 (84.0)
The etiology of HBV 83 (78.3) 487 (64.8) 0.01 84 (79.2) 0.79
hepatocellular carcinoma HCV 6 (5.7) 76 (10.1) 3 (2.8)
NBNC and alcohol 13 (12.2) 77 (10.3) 15 (14.2)
HBV and HCV 0 ( 25 (3.3) 0 (
Unknown 4 (3.8) 86 (11.5) 4 (3.8)
Values are presented as number (%) unless otherwise indicated. CCRT, concurrent chemoradiotherapy; KLCSG, Korean Liver
Cancer Study Group; LCSGJ, Liver Cancer Study Group of Japan; TNM, tumor, node, metastasis; BCLC, Barcelona Clinic
Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-HBV or non-HCV hepatitis.
Hong In Yoon, The Clinical Benefit of CCRT on HCC
VOLUME 48  NUMBER 1  JANUARY  2016 193
mg/day during the first and last weeks of RT [12]. Most 
patients received HAIC with 5-FU (at a dose of 500 mg/m2
for 5 hours on days 1-3) and cisplatin (at a dose of 60 mg/m2
for 2 hours on day 2) for three to 12 cycles in accordance to
the treatment response after CCRT. In cases of multiple 
tumors, the primary and adjacent tumors were irradiated. In
12 patients (16.0%) among the 75 multiple tumor patients, 
additional tumors outside of the RT field were treated using
a transcatheter arterial chemoembolization (TACE) [13] or
transcatheter arterial chemoinfusion (TACI).
2) Treatment modality in non-CCRT group
In the non-CCRT group, 12 patients were treated with sur-
gical resection (11.3%), one (0.9%) with local ablation ther-
apy, 78 (73.6%) with TACE, 13 patients (12.3%) with local
chemotherapy such as TACI or transcatheter arterial lipi-
odol-chemoinfusion, and two (1.9%) with systemic chemot-
herapy. The KLCSG database only included information of
the treatment type; therefore, detailed treatment methods are
unknown.
3) End points
The overall actuarial survival (OS) was calculated from the
RT start date to the date of death or last follow-up for the
CCRT group and from the treatment date to the date of death
or last contact for non-CCRT group. We compared the OS
rates between the two groups.
4) Subgroup analyses
In additional subgroups according to prognostic factors,
we compared the OS rate between the CCRT and non-CCRT
groups. We considered tumor size ≥ 5 cm, treatment period,
BCLC stage C, portal vein invasion (PVI), or major (lobar or
main) PVI as prognostic factors to determine each subgroup. 
5) Statistical considerations
As described in Table 1, the CCRT group and KLCSG 
cohort differed significantly in several clinical factors, includ-
ing age, tumor size, TNM stage by LCSGJ, T stage, PVI,
BCLC stage, and the etiology of HCC. Therefore, we per-
formed propensity score matching to adjust for seven poten-
tially significant patient characteristics that differed
significantly between the CCRT group and the KLCSG 
cohort (age, tumor size, TNM stage by the LCSGJ, T stage,
BCLC stage, the etiology of HCC, and PVI). Using multivari-
ate logistic regression analyses to make weighted probabili-
ties, propensity scores were calculated to determine the effect
of characteristics on the treatment modality. Propensity score
matching determined that the non-CCRT group of 106 
patients who underwent other monotherapies from the
KLCSG database matched with the 106 patients of the CCRT
group from the YCC database. To appraise the degree of bal-
ancing, we compared clinical and prognostic factors between
the two groups using Pearson’s chi-square tests or Fisher
exact tests for nominal variables, and Mann-Whitney U tests
for continuous variables. We calculated OS rates using the
Kaplan-Meier method and log-rank tests to assess the sur-
vival differences. We performed univariate and multivariate
analyses to evaluate all prognostic factors influencing OS
using Cox’s regression model. We performed a multivariate
analysis using backwards elimination to stay in the model.
The hazard ratios (HR) are given with 95% confidence inter-
vals (95% CI). We considered p-values less than 0.05 to be
statistically significant. SPSS ver. 20.0 (IBM Co., Armonk,
NY) was used for all analyses.
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Fig. 1.  Kaplan-Meier curve of overall survival (OS) 
according to the two treatment groups. Kaplan-Meier
curve depicted that concurrent chemoradiotherapy
(CCRT) (median OS, 11.4 months; 2-year OS, 27.3%; 5-year
OS, 10.4%) significantly improved OS compared to the
non-CCRT group (median OS, 6.6 months; 2-year OS,
18.9%; 5-year OS, 8.5%; p=0.02).
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Results
1. Patient characteristics after propensity score matching
The patient characteristics of the two groups after propen-
sity score matching are listed in Table 1. Before propensity
score matching, there were significant differences in patient
characteristics, including age (p < 0.001), tumor size (p < 0.001),
TNM stage (p < 0.001), T stage (p < 0.001), PVI (p < 0.001),
BCLC staging (p < 0.001) and the etiology of HCC (p=0.01)
between the CCRT group and KLCSG cohort. After propen-
sity score matching, Table 1 demonstrates that all clinical and
prognostic factors were balanced between the CCRT and
non-CCRT groups. 
2. Comparison of overall survival rates between the two
treatment groups
The median follow-up period for surviving patients was
63 months for the CCRT group and 90 months for the non-
CCRT group. After propensity score matching analyses, 
Kaplan-Meier curves depicted that the CCRT group (median
OS, 11.4 months; 5-year OS, 10.4%) had significantly better
OS than the non-CCRT group (median OS, 6.6 months; 
5-year OS, 8.5%; p=0.02) (Fig. 1).
3. Prognostic factors analyses
We performed prognostic factor analyses using a Cox 
regression model for 212 patients in both groups (Table 2).
Univariate analyses showed that tumor size (HR, 1.08; 95%
CI, 1.03 to 1.12; p < 0.001), TNM stage by LCSGJ (III vs. 
IV-A; HR, 0.6; 95% CI, 0.45 to 0.8; p=0.001), T stage (T3 vs.
T4; HR, 0.6; 95% CI, 0.45 to 0.8; p=0.001), PVI (no vs. yes; HR,
0.57; 95% CI, 0.39 to 0.82; p=0.003), BCLC staging system (B
vs. C; HR, 0.54; 95% CI, 0.36 to 0.81; p=0.003) and CCRT (no
vs. yes; HR, 1.41; 95% CI, 1.06 to 1.87; p=0.02) were signifi-
cantly associated with OS. The treatment period did not 
affect OS. In multivariate analyses using all prognostic 
factors, CCRT (no vs. yes; HR, 1.48; 95% CI, 1.11 to 1.97;
p=0.007), tumor size (HR, 1.08; 95% CI, 1.04 to 1.12; p < 0.001)
and BCLC staging system (B vs. C; HR, 0.54; 95% CI, 0.36 to
0.8; p=0.003) were independent prognostic factors for OS. 
4. Subgroup analyses
Because CCRT showed statistically significant differences
after prognostic factor analyses, we evaluated the survival
benefit of CCRT in several subgroups. We assessed whether
CCRT influenced OS as a prognostic factor in each subgroup
using a Cox regression model (Fig. 2). CCRT was a statisti-
cally significant factor for OS, and the CCRT group showed
significantly better OS than the non-CCRT group in sub-
groups with a tumor size ≥ 5 cm (no vs. yes; HR, 1.75; 95%
CI, 1.3 to 2.37; p < 0.001). In the subgroup of patients who
underwent treatment from 2003 to 2005, CCRT was also a
significant factor for OS (no vs. yes; HR, 1.91; 95% CI, 1.15 to
3.17; p=0.01). CCRT-treated patients showed longer OS with
a statistical significance in the BCLC C subgroup (no vs. yes;
Table 2. Prognostic factors for overall survival based on Cox proportional-hazards model (n=212)
Variable
Univariate analyses Multivariate analyses
HR (95% CI) p-value HR (95% CI) p-value
Age (yr) 1 (0.99-1.01) 0.63 - -
Tumor size (cm) 1.08 (1.03-1.12) < 0.001 1.08 (1.04-1.12) < 0.001
Sex (male vs. female) 1.17 (0.8-1.72) 0.42 - -
Growth pattern (single vs. multiple) 0.84 (0.62-1.15) 0.29 - -
Treatment period Reference 0.54 - -
(< 2003, 2003-2005, > 2005) 1.21 (0.77-1.9)
1.23 (0.85-1.76)
TNM stage by LCSGJ (III vs. IV-A) 0.6 (0.45-0.8) 0.001 - -
T stage (T3 vs. T4) 0.6 (0.45-0.8) 0.001 - -
N stage (N0 vs. N1) 1.03 (0.61-1.75) 0.9 - -
Portal vein invasion (no vs. yes) 0.57 (0.39-0.82) 0.003 - -
BCLC staging system (B vs. C) 0.54 (0.36-0.81) 0.003 0.54 (0.36-0.8) 0.003
CCRT (no vs. yes) 1.41 (1.06-1.87) 0.02 1.48 (1.11-1.97) 0.007
HR, hazard ratio; CI, confidence interval; TNM, tumor, node, metastasis; LCSGJ, Liver Cancer Study Group of Japan; BCLC,
Barcelona Clinic Liver Cancer; CCRT, concurrent chemoradiotherapy.
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HR, 0.54; 95% CI, 0.36 to 0.8; p=0.04). In the PVI subgroup,
CCRT-treated patients showed a longer median survival, 
although this was not statistically significant. However,
CCRT was significantly related to OS in the major PVI sub-
group (no vs. yes; HR, 2.07; 95% CI, 1.35 to 3.16; p=0.001).
Discussion
In this study, all clinical and prognostic factors were 
balanced between the two groups after matching. The CCRT
group showed a significantly better OS than the non-CCRT
group. CCRT, tumor size, and BCLC staging system were 
independent prognostic factors for OS on multivariate analy-
ses. CCRT was also a significant factor for OS in each 
subgroup of patients receiving treatment from 2003 to 2005,
having tumor size ≥ 5 cm, BCLC stage C, or showing major
PVI.
However, special considerations are required to interpret
the findings of this study due to the following limitations.
First, this was a retrospective study, which was an unavoid-
able weakness. However, it is believed that a propensity
score analytic approach could minimize this limitation. 
Second, we did not include patients receiving sorafenib, as
most patients were treated for HCC before the era of 
sorafenib. Although our results show that the OS of CCRT
group was comparable to that reported for sorafenib [19,20],
we suggest that prospective randomized trials comparing
CCRT to sorafenib are be necessary. Third, two different
databases were utilized for this study. In 2003, for the first
time, the KLCSG and the National Cancer Center (NCC) of
Korea produced a clinical practice guideline in Korea. Since
2003, all Korean institutions, including our own, have com-
plied with the KLCSG guidelines, and most of the research
publications from our institution indicate that we have diag-
nosed HCC based on the KLCSG guidelines [10,13]. Despite
this limitation, we believe that the characteristics of patients
included in the two databases should not be very different.
However, since the treatment period of these two databases
was different, we analyzed the effect of the treatment period
in order to adjust for such differences. The treatment period
used for the KLCSG database was from 2003 to 2005. Thus,
we classified the treatment period as starting from 2003 until
2005. In the analyses of prognostic factors, the treatment 
period was not a significant factor for OS (Table 2). In the
subgroup analysis of patients treated between 2003 and 2005,
the CCRT group showed a significantly higher OS (Fig. 2).
Due to the different databases, it is also possible that those
in the non-CCRT group may have been in more advanced
stages of HCC. However, given that the CCRT group
showed a tumor growth pattern that was similar to the 
non-CCRT group, albeit with more major PVI (CCRT, 80.2%;
non-CCRT, 30.2%; p < 0.001), we do not believe that the 
non-CCRT group patients in this study were of a more 
advanced stage at the time of diagnosis. Based on this, we
believe that the utilization of two databases should not have
affected our findings or conclusions. Fourth, we could not
use AFP levels and performance status of patients for
propensity score matching analysis as the KLCSG databases
did not include information regarding the AFP level and 
performance status. In future studies, AFP levels and per-
formance status need to be considered as they could be 
associated with overall survival. Fifth, at least a certain por-
tion of patients in the CCRT group might have been highly
selected patients, which might have in turn influenced the
treatment outcome, given that all patients in the CCRT group
Tumor size ≥ 5 cm (187)
Treatment period 2003-2005 (127)
BCLC stage C (177)
Portal vein invasion (170)
Major portal vein invasion (117)
Subgroup
  (No. of patients)
Non-CCRT better CCRT better
Non-CCRT
5.4
6.6
5.3
5.3
4.2
CCRT
11.4
22.6
10   
10   
10   
Median OS (mo)
< 0.001
 0.01
 0.04
   0.098
   0.001
p-valueHazard ratio
0 1 2 3 4 5
Fig. 2. The difference in overall survival (OS) between the two treatment groups in each subgroup. CCRT, concurrent chemoradio-
therapy; BCLC, Barcelona Clinic Liver Cancer.
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were treated at the tertiary referral hospital only. Thus, fur-
ther prospective randomized clinical trials are necessary to
prove our findings.
A multimodality treatment, such as CCRT, has been repe-
atedly proven to be effective in advanced stages of several
cancers. However, the survival benefit of RT or chemother-
apy alone as well as CCRT for HCC has not been fully eluci-
dated. Nevertheless, several combined treatments, such as
TACE plus RT, or CCRT with HAIC have been utilized in 
attempts to improve the oncologic outcome for HCC. There-
fore, several studies regarding a combination of RT and
TACE have reported favorable response rates and overall
survival for HCC with PVI [21,22]. Furthermore, some stud-
ies investigating the combination of RT with concurrent 
hepatic artery chemotherapy have also demonstrated a 
favorable effect on overall survival, with a median survival
of 11-15.2 months for unresectable primary hepatobiliary
cancer [14,23]. These results are comparable to the results of
this study. The purpose of using CCRT with HAIC was to
enhance the local radio-therapeutic effect and to reduce 
intrahepatic HCC spread. As such, although every treatment
for HCC is controversial, we anticipated that concurrently
combining HAIC with RT would produce a synergistic ther-
apeutic effect. Based on these concepts of a multimodality
approach, our group previously reported that CCRT 
improved response rates and survival for locally advanced
HCC with PVI [12]. In a more recent study, it was reported
that CCRT or a combination of RT and TACE produced an
excellent intrahepatic control as well as prolonged survival
[24]. The median OS was significantly longer in the combined
RT and TACE group (15.3 months) and CCRT group (12.8
months) than in TACE alone (7.5 months) and HAIC alone
(8.2 months) for huge HCC larger than 10 cm. In the sub-
group analysis of this study, the CCRT group had signifi-
cantly better OS compared to the non-CCRT group for locally
advanced HCC with major PVI. Our findings suggest that
CCRT could be a feasible treatment option for HCC with
major PVI.
Furthermore, CCRT can potentially cure selected locally
advanced patients by inducing down-staging and conversion
to resectable status. In a recent study, our group reported
that CCRT increased resectability by down-staging tumors
[25]. Tumor resectability was assessed by liver surgeons and
radiologists after completing CCRT, using all computed 
tomography or magnetic resonance imaging scans. Curative
resection was performed for patients showing radiologic
findings that all gross lesions could be resected with a clear
margin. Among a total of 243 patients who underwent
CCRT, 41 patients (16.9%) received curative resection. Down-
staging of T classification after CCRT was observed in 32
(78.0%). On Kaplan-Meier survival curves, 41 patients who
received curative resection showed significantly higher 
5-year OS (49.6%) than the others (0%, p < 0.001). In this
study, 12 patients (11.3%) underwent curative resection, and
10 (83.3%) of them showed down-staging of T classification.
In the CCRT group, the 12 patients who received a curative
resection showed a significantly better 5-year OS (72.7%)
than the other patients (2.5%, p < 0.001) and showed a 
significantly higher 5-year OS than patients who underwent
resection as the first line of treatment in the non-CCRT group
(16.7%, p=0.002). We consider CCRT as a potential contribu-
tor to a better treatment outcome in locally advanced HCC
patients without extra-hepatic visceral metastasis. However,
a well-designed further prospective study would be needed
to prove a down-staging effect of CCRT for locally advanced
HCC.
Conclusion
In conclusion, this study used propensity score matching
analyses to show that CCRT was significantly associated
with better OS for locally advanced HCC. We believe that in
patients with good performance status and normal liver
function, CCRT could be a feasible treatment option for 
locally advanced HCC, despite lobar or main PVI. Neverthe-
less, all of these findings need to be validated in prospective
clinical trials.
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